Patrick O. McGowan, Ph.D., is one of the Solve ME/CFS Initiative 2011 funded investigators. McGowan is an assistant professor in the Department of Biological Sciences, University of Toronto at Scarborough. He will talk about his latest results from our grant funding. McGowan used blood samples from the SolveCFS BioBank to identify the chemical modifications (e.g., methylation) to the DNA that is different in ME/CFS patients compared to healthy people. This type of research will help explain the immune dysfunction of ME/CFS.
The first study to report epigenetic modifications throughout the genome in female ME/CFS patients compared to a matched sample of healthy controls. Ā ThisĀ research conducted in partnership and funded by the Solve ME/CFS Initiative (SMCI) was published todayĀ in the high impact and open access journal PLOS ONE (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0104757).
The Solve ME/CFS Initiative launched our Research Institute Without Walls in 2010 and Dr. Patrick McGowan was one of our first grantees to use this innovative infrastructure. Together with his graduate student, Will de Vega and SMCIās Scientific Director, Suzanne D. Vernon, they found evidenceĀ of distinct epigenetic profiles in immune and other physiologically relevant genes in a selected group of female ME/CFS patients.Ā Will de Vega, who performed much of the work, is a PhD candidate in the department of Cell and Systems Biology at the University of Toronto. His thesis research concerns how environmental factors and ME/CFS impact immunological processes, and their effects on clinically relevant phenotypes.Ā
Epigenetic modifications affect the way genes are turned on or off without changing the inherited gene sequences. āKnowledge about the epigenetics of ME/CFS could potentially lead to alternative treatment options for sufferers, from targeted lifestyle interventions to new pharmacological treatmentsā, notes McGowan. There were many epigenetic modifications in and around immune genes that affect the way these genes are regulated and expressed. These types of changes would be expected to affect immune cell function in ME/CFS patients. āThis is the first in a series of exciting results coming from McGowanās lab at the University of Torontoā, says Suzanne D. Vernon. āBy understanding these epigenetic differences in the immune cells of ME/CFS patients, we can begin to decipher the molecular mechanisms of the immune dysfunction that we suspect is at the root of ME/CFSā.
McGowan started this ME/CFS epigenetic research in 2012. His quick success is a testament to the power of patient-centered research approach used by the Solve ME/CFS Initiative. āOur study would not have been possible without the funding provided by the Solve ME/CFS Initiative, patient samples from the SolveCFS BioBank, and the collaborative support of the Initiativeās scientific director Dr. Suzanne D. Vernonā says McGowan.
